S&P 500   4,322.30 (-0.64%)
DOW   34,134.43 (-0.10%)
QQQ   340.54 (-1.17%)
AAPL   158.74 (-0.59%)
MSFT   298.51 (+0.61%)
FB   294.81 (+0.06%)
GOOGL   2,580.51 (-0.16%)
AMZN   2,792.38 (+0.54%)
TSLA   838.07 (-10.60%)
NVDA   219.71 (-3.52%)
BABA   111.75 (-1.43%)
NIO   21.06 (-7.06%)
AMD   102.53 (-7.39%)
CGC   6.83 (-5.53%)
MU   78.56 (-4.16%)
GE   89.28 (-0.04%)
T   24.02 (-0.95%)
F   19.56 (-1.76%)
DIS   135.08 (+1.11%)
AMC   14.52 (-8.91%)
PFE   53.53 (+0.98%)
ACB   3.79 (-6.65%)
BA   188.83 (-2.80%)
S&P 500   4,322.30 (-0.64%)
DOW   34,134.43 (-0.10%)
QQQ   340.54 (-1.17%)
AAPL   158.74 (-0.59%)
MSFT   298.51 (+0.61%)
FB   294.81 (+0.06%)
GOOGL   2,580.51 (-0.16%)
AMZN   2,792.38 (+0.54%)
TSLA   838.07 (-10.60%)
NVDA   219.71 (-3.52%)
BABA   111.75 (-1.43%)
NIO   21.06 (-7.06%)
AMD   102.53 (-7.39%)
CGC   6.83 (-5.53%)
MU   78.56 (-4.16%)
GE   89.28 (-0.04%)
T   24.02 (-0.95%)
F   19.56 (-1.76%)
DIS   135.08 (+1.11%)
AMC   14.52 (-8.91%)
PFE   53.53 (+0.98%)
ACB   3.79 (-6.65%)
BA   188.83 (-2.80%)
S&P 500   4,322.30 (-0.64%)
DOW   34,134.43 (-0.10%)
QQQ   340.54 (-1.17%)
AAPL   158.74 (-0.59%)
MSFT   298.51 (+0.61%)
FB   294.81 (+0.06%)
GOOGL   2,580.51 (-0.16%)
AMZN   2,792.38 (+0.54%)
TSLA   838.07 (-10.60%)
NVDA   219.71 (-3.52%)
BABA   111.75 (-1.43%)
NIO   21.06 (-7.06%)
AMD   102.53 (-7.39%)
CGC   6.83 (-5.53%)
MU   78.56 (-4.16%)
GE   89.28 (-0.04%)
T   24.02 (-0.95%)
F   19.56 (-1.76%)
DIS   135.08 (+1.11%)
AMC   14.52 (-8.91%)
PFE   53.53 (+0.98%)
ACB   3.79 (-6.65%)
BA   188.83 (-2.80%)
S&P 500   4,322.30 (-0.64%)
DOW   34,134.43 (-0.10%)
QQQ   340.54 (-1.17%)
AAPL   158.74 (-0.59%)
MSFT   298.51 (+0.61%)
FB   294.81 (+0.06%)
GOOGL   2,580.51 (-0.16%)
AMZN   2,792.38 (+0.54%)
TSLA   838.07 (-10.60%)
NVDA   219.71 (-3.52%)
BABA   111.75 (-1.43%)
NIO   21.06 (-7.06%)
AMD   102.53 (-7.39%)
CGC   6.83 (-5.53%)
MU   78.56 (-4.16%)
GE   89.28 (-0.04%)
T   24.02 (-0.95%)
F   19.56 (-1.76%)
DIS   135.08 (+1.11%)
AMC   14.52 (-8.91%)
PFE   53.53 (+0.98%)
ACB   3.79 (-6.65%)
BA   188.83 (-2.80%)
NASDAQ:HSKA

Heska Stock Forecast, Price & News

$130.58
-7.65 (-5.53%)
(As of 01/27/2022 03:20 PM ET)
Add
Compare
Today's Range
$130.31
$140.65
50-Day Range
$138.23
$185.30
52-Week Range
$135.25
$275.94
Volume
1,312 shs
Average Volume
67,943 shs
Market Capitalization
$1.40 billion
P/E Ratio
687.30
Dividend Yield
N/A
Beta
1.56
30 days | 90 days | 365 days | Advanced Chart
Receive HSKA News and Ratings via Email

Sign-up to receive the latest news and ratings for Heska and its competitors with MarketBeat's FREE daily newsletter.


Heska logo

About Heska

Heska Corp. engages in the provision of veterinary and animal health diagnostic, and specialty products. It operates through the North America and International segments. The North America segment includes the United States, Canada, and Mexico. The International segment involves Australia, France, Germany, Italy, Malaysia, Spain, and Switzerland. The company was founded by Robert B. Grieve and Lynnor B. Stevenson in 1988 and is headquartered in Loveland, CO.

Headlines

Heska (NASDAQ:HSKA) Sets New 1-Year Low at $137.75
January 26, 2022 |  americanbankingnews.com
Heska (NASDAQ:HSKA) Trading 4.2% Higher
January 21, 2022 |  americanbankingnews.com
Heska (NASDAQ:HSKA) Sees Strong Trading Volume
January 20, 2022 |  americanbankingnews.com
Heska (NASDAQ:HSKA) Sets New 12-Month Low at $146.49
January 13, 2022 |  americanbankingnews.com
See More Headlines

Industry, Sector and Symbol

Industry
Diagnostic substances
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:HSKA
Employees
602
Year Founded
N/A

Sales & Book Value

Annual Sales
$197.32 million
Cash Flow
$1.15 per share
Book Value
$30.36 per share

Profitability

Net Income
$-14.40 million
Pretax Margin
-0.70%

Debt

Price-To-Earnings

Miscellaneous

Free Float
9,618,000
Market Cap
$1.40 billion
Optionable
Not Optionable

Company Calendar

Last Earnings
11/04/2021
Today
1/27/2022
Next Earnings (Estimated)
2/22/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

2.74 out of 5 stars

Medical Sector

56th out of 1,419 stocks

Diagnostic Substances Industry

1st out of 25 stocks

Analyst Opinion: 3.4Community Rank: 4.3Dividend Strength: 0.0Insider Behavior: 4.2Valuation: 1.9 5 -4 -3 -2 -1 -












Heska (NASDAQ:HSKA) Frequently Asked Questions

Is Heska a buy right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Heska in the last twelve months. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Heska stock.
View analyst ratings for Heska
or view top-rated stocks.

How has Heska's stock price been impacted by Coronavirus (COVID-19)?

Heska's stock was trading at $81.83 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, HSKA stock has increased by 59.6% and is now trading at $130.58.
View which stocks have been most impacted by COVID-19
.

When is Heska's next earnings date?

Heska is scheduled to release its next quarterly earnings announcement on Tuesday, February 22nd 2022.
View our earnings forecast for Heska
.

How were Heska's earnings last quarter?

Heska Co. (NASDAQ:HSKA) issued its quarterly earnings results on Thursday, November, 4th. The medical research company reported ($0.19) EPS for the quarter, missing the consensus estimate of $0.04 by $0.23. The medical research company earned $60.24 million during the quarter, compared to analyst estimates of $63.80 million. Heska had a net margin of 0.75% and a trailing twelve-month return on equity of 1.07%. The firm's revenue for the quarter was up 6.4% compared to the same quarter last year. During the same quarter last year, the company earned ($0.25) earnings per share.
View Heska's earnings history
.

What price target have analysts set for HSKA?

6 analysts have issued 1 year price objectives for Heska's stock. Their forecasts range from $190.00 to $310.00. On average, they anticipate Heska's share price to reach $250.83 in the next twelve months. This suggests a possible upside of 92.1% from the stock's current price.
View analysts' price targets for Heska
or view top-rated stocks among Wall Street analysts.

Who are Heska's key executives?

Heska's management team includes the following people:

What is Kevin S. Wilson's approval rating as Heska's CEO?

5 employees have rated Heska CEO Kevin S. Wilson on Glassdoor.com. Kevin S. Wilson has an approval rating of 57% among Heska's employees. This puts Kevin S. Wilson in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Heska own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Heska investors own include Gilead Sciences (GILD), Exxon Mobil (XOM), Netflix (NFLX), Biogen (BIIB), AbbVie (ABBV), Amgen (AMGN), Broadcom (AVGO), Alibaba Group (BABA), Exelixis (EXEL) and Merck & Co., Inc. (MRK).

What is Heska's stock symbol?

Heska trades on the NASDAQ under the ticker symbol "HSKA."

Who are Heska's major shareholders?

Heska's stock is owned by many different retail and institutional investors. Top institutional investors include Riverbridge Partners LLC (2.86%), Manning & Napier Group LLC (0.64%), Russell Investments Group Ltd. (0.55%), Anderson Hoagland & Co. (0.12%), State of Alaska Department of Revenue (0.07%) and Louisiana State Employees Retirement System (0.05%). Company insiders that own Heska stock include Bonnie J Trowbridge, Catherine Grassman, Jason D Aroesty, Kevin S Wilson, Nancy Wisnewski and Sharon J Larson.
View institutional ownership trends for Heska
.

Which major investors are selling Heska stock?

HSKA stock was sold by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., Manning & Napier Group LLC, Strs Ohio, Anderson Hoagland & Co., and State of Alaska Department of Revenue. Company insiders that have sold Heska company stock in the last year include Catherine Grassman, Nancy Wisnewski, and Sharon J Larson.
View insider buying and selling activity for Heska
or view top insider-selling stocks.

Which major investors are buying Heska stock?

HSKA stock was acquired by a variety of institutional investors in the last quarter, including Riverbridge Partners LLC, Ellsworth Advisors LLC, IMPACTfolio LLC, Tokio Marine Asset Management Co. Ltd., Navigation Wealth Management Inc., New York State Teachers Retirement System, and Louisiana State Employees Retirement System.
View insider buying and selling activity for Heska
or or view top insider-buying stocks.

How do I buy shares of Heska?

Shares of HSKA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Heska's stock price today?

One share of HSKA stock can currently be purchased for approximately $130.58.

How much money does Heska make?

Heska has a market capitalization of $1.40 billion and generates $197.32 million in revenue each year. The medical research company earns $-14.40 million in net income (profit) each year or $0.19 on an earnings per share basis.

How many employees does Heska have?

Heska employs 602 workers across the globe.

What is Heska's official website?

The official website for Heska is www.heska.com.

Where are Heska's headquarters?

How can I contact Heska?

Heska's mailing address is 3760 ROCKY MOUNTAIN AVENUE, LOVELAND CO, 80538. The medical research company can be reached via phone at (970) 493-7272, via email at [email protected], or via fax at 970-619-3003.


This page was last updated on 1/27/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.